Method for in vitro diagnosis or prognosis of colon cancer
AssigneesBiomerieux, Hospices Civils De Lyon
InventorsFrançois Mallet, Nathalie Mugnier, Philippe Perot
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.
Claims18
A method for the in vitro diagnosis or prognosis of colon cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID NOs:
- 1 to 285 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOs:
- 1 to 285.
The method of at least two nucleic acid sequences, which have been isolated, as a molecular marker for the in vitro diagnosis or prognosis of colon cancer, wherein the two nucleic acid sequences consist of:
- (i) at least two DNA sequences chosen from the sequences SEQ ID NOs:
- 1 to 285, or
- (ii) at least two DNA sequences respectively complementary to at least two sequences chosen from the sequences SEQ ID NOs:
- 1 to 285, or
- (iii) at least two DNA sequences which exhibit at least 99% identity with two sequences as defined in (i) and (ii), or
- (iv) at least two RNA sequences which are respectively the transcription product of two sequences chosen from the sequences as defined in (i), or
- (v) at least two RNA sequences which are the transcription product of at least two sequences chosen from the sequences which exhibit at least 99% identity with the sequences as defined in (i).
A kit for the in vitro diagnosis or prognosis of colon cancer in a biological sample taken from a patient, which comprises at least two respectively specific binding partners of at least two expression products of at least two nucleic acid sequences chosen from the sequences identified in SEQ ID NOs:
- 1 to 285 or from the sequences which exhibit at least 99% identity with the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 285 and no more than 285 specific binding partners of the expression products of the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 285 or of the nucleic acid sequences which exhibit at least 99% identity with the nucleic acid sequences identified in SEQ ID NOs:
- 1 to 285.
A method for evaluating the efficacy of a treatment and/or a progression in colon cancer, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said two nucleic acid sequences being chosen from the sequences identified in SEQ ID NOs:
- 1 to 285 or from the sequences which exhibit at least 99% identity respectively with the sequences identified in SEQ ID NOs:
- 1 to 285.
Dependencies are inferred from the claim text.